SCHEMBL3247063

SCHEMBL3247063

NCc1nc2cc(Br)ccc2s1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.65
UBE2T Q9NPD8 1/20 0.58
ASIC3 Q9UHC3 1/20 0.58
DYRK1A Q13627 1/20 0.45
TRPV1 Q8NER1 3/20 0.44
AKR1B1 P15121 2/20 0.42
PPARA Q07869 2/20 0.41
CYP2A6 P11509 1/20 0.41
HDAC6 Q9UBN7 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GAA P10253 2/20 0.40
MAPK1 P28482 1/20 0.40
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
BACE1 P56817 1/20 0.39
ADORA1 P30542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20511957 0.98 LOXL2 (0.63) LOXL2UBE2TASIC3DYRK1ATRPV1
Hydrochloric Acid SCHEMBL29456890 0.98 LOXL2 (0.63) LOXL2UBE2TASIC3DYRK1ATRPV1
Iodide SCHEMBL31511840 0.98 LOXL2 (0.63) LOXL2UBE2TASIC3DYRK1ATRPV1
SCHEMBL20509831 0.86 UBE2T (0.58) LOXL2UBE2TASIC3DYRK1AAKR1B1
SCHEMBL201370 0.84 DYRK1A (0.46) LOXL2UBE2TASIC3DYRK1ATRPV1
SCHEMBL2947099 0.82 NPC1 (0.63) LOXL2UBE2TASIC3DYRK1ATRPV1
SCHEMBL9675635 0.82 LOXL2 (0.47) LOXL2UBE2TASIC3DYRK1ATRPV1
SCHEMBL31003151 0.82 NPC1 (0.63) LOXL2UBE2TASIC3DYRK1ATRPV1
SCHEMBL27281641 0.81 DYRK1A (0.44) LOXL2UBE2TASIC3DYRK1ATRPV1
SCHEMBL25322263 0.80 PPARA (0.47) LOXL2UBE2TASIC3DYRK1ATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016941-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2024-01-18 US disclosed
US-20240016941-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2024-01-18 US disclosed
WO-2021191240-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2021-09-30 WO disclosed
US-9428528-B2 Phenicol antibacterials ZOETIS SERVICES LLC (US) 2016-08-30 US disclosed
US-9428528-B2 Phenicol antibacterials ZOETIS SERVICES LLC (US) 2016-08-30 US disclosed
US-9428528-B2 Phenicol antibacterials ZOETIS SERVICES LLC (US) 2016-08-30 US disclosed
US-20160194342-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC (US) 2016-07-07 US disclosed
US-20160194342-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC (US) 2016-07-07 US disclosed
US-20160194342-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC (US) 2016-07-07 US disclosed
US-9340564-B2 Phenicol antibacterials ZOETIS SERVICES LLC (US) 2016-05-17 US disclosed
US-9073894-B2 Phenicol antibacterials ZOETIS SERVICES LLC (US) 2015-07-07 US disclosed
US-9073894-B2 Phenicol antibacterials ZOETIS SERVICES LLC (US) 2015-07-07 US disclosed
US-9073894-B2 Phenicol antibacterials ZOETIS SERVICES LLC (US) 2015-07-07 US disclosed
EP-2822934-A1 PHENICOL ANTIBACTERIALS Zoetis LLC (US) 2015-01-14 EP disclosed
WO-2013134061-A1 PHENICOL ANTIBACTERIALS ZOETIS LLC (US) 2013-09-12 WO disclosed
US-20130237502-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC 2013-09-12 US disclosed
US-20130237502-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC 2013-09-12 US disclosed
US-20130237502-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC 2013-09-12 US disclosed
WO-2010001220-A1 NEW 1,2,4-TRIAZINE DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF MUTABILIS SA (FR) 2010-01-07 WO disclosed
EP-2141164-A1 New 1,2,4-triazine derivatives and biological applications thereof Mutabilis (FR) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237502-A1 PHENICOL ANTIBACTERIALS MRPL21, TTL, CTSL LOXL2 38/4885UBE2T 798/4885ASIC3 2672/4885
US-20240016941-A1 COMBINATION THERAPY CFTR, ABCB11, SLC26A4 LOXL2 3554/4885UBE2T 2566/4885ASIC3 420/4885
US-20160194342-A1 PHENICOL ANTIBACTERIALS MRPL21, TTL, CTSL LOXL2 38/4885UBE2T 798/4885ASIC3 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.